Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes

被引:62
作者
Jones, Stephanie [1 ]
Peng, Peter D. [1 ]
Yang, Shicheng [1 ]
Hsu, Cary [1 ]
Cohen, Cyrille J. [1 ]
Zhao, Yangbing [1 ]
Abad, John [1 ]
Zheng, Zhili [1 ]
Rosenberg, Steven A. [1 ]
Morgan, Richard A. [1 ]
机构
[1] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
POLYMERASE-CHAIN-REACTION; ADOPTIVE IMMUNOTHERAPY; CANCER REGRESSION; THERAPY; MUTAGENESIS; RECOGNITION; MELANOMA; MAINTAIN;
D O I
10.1089/hum.2008.048
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Lentiviral vectors containing promoters of distinct origins, that is, strong viral promoters (cytomegalovirus [CMV] and murine stem cell virus [MSCV]), a cellular promoter (phosphoglycerate kinase [PGK]), and two composite promoters (CAG [a composite promoter sequence comprised of the CMV enhancer and portions of the chicken beta-actin promoter and the rabbit beta-globin gene] and SV40/CD43), were used to evaluate green fluorescent protein (GFP) reporter gene expression in human primary peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes (TILs). In PBLs, vectors containing the MSCV promoter were found to be optimal for expression in both minimally stimulated and highly activated lymphocytes. The stability of gene expression was monitored for up to 7 weeks in culture and the MSCV promoter-containing vector was found to be comparable to the cellular PGK promoter-containing vector. The MSCV promoter-containing lentiviral vector was also the most active in transduced TILs and these cells retained biological activity as measured by antimelanoma antigen reactivity. Using the knowledge gained in comparing individual promoters, a series of two-gene-containing lentiviral vectors was constructed in an attempt to produce the alpha and beta chains of antitumor antigen T cell receptors (TCRs). Dual-promoter or internal ribosome entry site (IRES)-containing vector designs were evaluated and found to be unable to produce both chains of the TCR in amounts that led to significant biological activity. In contrast, if the alpha and beta chains were linked by a 2A ribosomal skip peptide, both proper TCR chain pairing and biologically activity were observed. This paper emphasizes the need to optimize both promoter function and protein synthesis in constructs that require stoichiometric production of multiple protein subunits.
引用
收藏
页码:630 / 640
页数:11
相关论文
共 42 条
[1]   Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement [J].
Aiuti, A ;
Vai, S ;
Mortellaro, A ;
Casorati, G ;
Ficara, F ;
Andolfi, G ;
Ferrari, G ;
Tabucchi, A ;
Carlucci, F ;
Ochs, HD ;
Notarangelo, LD ;
Roncarolo, MG ;
Bordignon, C .
NATURE MEDICINE, 2002, 8 (05) :423-425
[2]   Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters [J].
Amendola, M ;
Venneri, MA ;
Biffi, A ;
Vigna, E ;
Naldini, L .
NATURE BIOTECHNOLOGY, 2005, 23 (01) :108-116
[3]   T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].
BLAESE, RM ;
CULVER, KW ;
MILLER, AD ;
CARTER, CS ;
FLEISHER, T ;
CLERICI, M ;
SHEARER, G ;
CHANG, L ;
CHIANG, YW ;
TOLSTOSHEV, P ;
GREENBLATT, JJ ;
ROSENBERG, SA ;
KLEIN, H ;
BERGER, M ;
MULLEN, CA ;
RAMSEY, WJ ;
MUUL, L ;
MORGAN, RA ;
ANDERSON, WF .
SCIENCE, 1995, 270 (5235) :475-480
[4]   Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence [J].
Cavalieri, S ;
Cazzaniga, S ;
Geuna, M ;
Magnani, Z ;
Bordignon, C ;
Naldini, L ;
Bonini, C .
BLOOD, 2003, 102 (02) :497-505
[5]   Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI [J].
Chinnasamy, Dhanalakshmi ;
Milsom, Michael D. ;
Shaffer, James ;
Neuenfeldt, James ;
Shaaban, Aimen F. ;
Margison, Geoffrey P. ;
Fairbairn, Leslie J. ;
Chinnasamy, Nachimuthu .
VIROLOGY JOURNAL, 2006, 3 (1)
[6]   Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR [J].
Cohen, CJ ;
Zheng, ZL ;
Bray, R ;
Zhao, YB ;
Sherman, LA ;
Rosenberg, SA ;
Morgan, RA .
JOURNAL OF IMMUNOLOGY, 2005, 175 (09) :5799-5808
[7]   Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].
Dudley, ME ;
Wunderlich, JR ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Restifo, NP ;
Royal, RE ;
Kammula, U ;
White, DE ;
Mavroukakis, SA ;
Rogers, LJ ;
Gracia, GJ ;
Jones, SA ;
Mangiameli, DP ;
Pelletier, MM ;
Gea-Banacloche, J ;
Robinson, MR ;
Berman, DM ;
Filie, AC ;
Abati, A ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357
[8]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[9]   High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector [J].
Gao, ZG ;
Golob, J ;
Tanavde, VM ;
Civin, CI ;
Hawley, RG ;
Cheng, L .
STEM CELLS, 2001, 19 (03) :247-259
[10]   Adoptive immunotherapy for cancer: building on success [J].
Gattinoni, L ;
Powell, DJ ;
Rosenberg, SA ;
Restifo, NP .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :383-393